Results 21 to 30 of about 1,725 (146)

In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates

Antibiotics, 2023
Limited oral antibiotic options exist for urinary tract infections (UTI) caused by ESBL-producing Enterobacterales. The aim of the study was to evaluate in vitro activity of omadacycline and comparator antibiotics against clinical ESBL-producing and non ...
Tyler J. Stone, Abdullah Kilic, John C. Williamson, Elizabeth L. Palavecino   +3 more
doaj   +1 more source

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects

Frontiers in Pharmacology, 2022
Objective: Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear whether the US-approved
Haijing Yang, Haijing Yang, Haijing Yang, Zhiwei Huang, Zhiwei Huang, Zhiwei Huang, Yuancheng Chen, Yuancheng Chen, Yuancheng Chen, Yusong Zhu, Guoying Cao, Guoying Cao, Guoying Cao, Jingjing Wang, Jingjing Wang, Jingjing Wang, Yan Guo, Yan Guo, Yan Guo, Jicheng Yu, Jicheng Yu, Jicheng Yu, Jufang Wu, Jufang Wu, Jufang Wu, Lichuan Liu, Jun Deng, Jing Liu, Harald Reinhart, Jing Zhang, Jing Zhang, Jing Zhang, Xiaojie Wu, Xiaojie Wu, Xiaojie Wu   +34 more
doaj   +1 more source

In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden

Microbiology Spectrum, 2021
Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects.
Angela Camporeale, Chaitanya Tellapragada, Jelena Kornijenko, Carl Erik Nord, Christian G. Giske   +4 more
doaj   +1 more source

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial

Frontiers in Medicine, 2023
IntroductionThe 2019 American Thoracic Society/Infectious Disease Society of America guidelines recommend respiratory fluoroquinolones to treat community-acquired bacterial pneumonia (CABP) in adults with comorbidities.
George D. Rodriguez, George D. Rodriguez, Nathan Warren, Roman Yashayev, Surya Chitra, Maria Amodio-Groton, Kelly Wright   +6 more
doaj   +1 more source

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Frontiers in Microbiology, 2022
In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus
Weiliang Zeng, Xiaotuan Zhang, Yan Liu, Yi Zhang, Mengxin Xu, Sipei Wang, Yao Sun, Tieli Zhou, Lijiang Chen   +8 more
doaj   +1 more source

Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

BMC Microbiology, 2020
Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens.
Meng Xiao, Jing-jing Huang, Ge Zhang, Wen-hang Yang, Fanrong Kong, Timothy Kudinha, Ying-chun Xu   +6 more
doaj   +1 more source

Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease

mSphere, 2023
Mycobacteroides abscessus is an opportunistic pathogen in people with structural lung conditions such as bronchiectasis, chronic obstructive pulmonary disease, and cystic fibrosis. Pulmonary M.
Binayak Rimal, Danielle A. Nicklas, Chandra M. Panthi, Christopher K. Lippincott, Daniel C. Belz, Elisa H. Ignatius, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane   +8 more
doaj   +1 more source

Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility

Microbiology Spectrum, 2022
Tetracycline-based combinations are increasingly used for serious carbapenem-nonsusceptible Acinetobacter baumannii (CNSAb) infections given their potent in vitro activity, synergism with other agents, and acceptable toxicity profile.
Taylor Abbey, Alesia Vialichka, Michele Jurkovic, Mark Biagi, Eric Wenzler   +4 more
doaj   +1 more source

Omadacycline therapy for Mycobacterium abscessus species infections

Internal Medicine Journal, Volume 53, Issue 12, Page 2257-2263, December 2023., 2023
Abstract Background Antimicrobial resistance and therapy‐related adverse effects make Mycobacterium abscessus treatment challenging. Omadacycline is a novel, bioavailable aminomethylcycline with favourable in vitro activity against M. abscessus. Aims To describe a case report and review the published literature describing outcomes for M.
Paul R. Ingram, Eva E. Jones, Bethwyn Allen, Ronan J. Murray, Terillee J. Keehner, Timothy J. Whitmore   +5 more
wiley   +1 more source

Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms

BioMed Research International, Volume 2023, Issue 1, 2023., 2023
Antimicrobial resistance (AMR) is a ubiquitous public health menace. AMR emergence causes complications in treating infections contributing to an upsurge in the mortality rate. The epidemic of AMR in sync with a high utilization rate of antimicrobial drugs signifies an alarming situation for the fleet recovery of both animals and humans.
Sarfraz Ahmed, Muhammad Zeeshan Ahmed, Safa Rafique, Seham Eid Almasoudi, Mohibullah Shah, Nur Asyilla Che Jalil, Suvash Chandra Ojha, Mahmoud Kandeel   +7 more
wiley   +1 more source